SEC Form 4 · accession 0001127602-16-048019
MERIDIAN BIOSCIENCE INC · VIVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence Baldini
Officer — EVP, Pres Global Operations
Period of report
Mar 24, 2016
Accepted (ET)
Apr 1, 2016 · 11:41 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000794172
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 90,376 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $19.56 | Mar 24, 2016 | A | 2,000 | A | — | Mar 24, 2026 | Common Stock | 2,000 | 2,000 | D |
Explanation of responses
- F1These options are awarded under the 2012 Stock Incentive Plan in connection with the Company's acquisition of Magellan Diagnostics, Inc. and vest in four equal installments from the date of grant (i.e., 25% per year until fully vested on March 24, 2020).